712313-35-4

712313-35-4 structure

Name: HAMI 3379
Chemical Name: 3-[(3-carboxycyclohexyl)carbamoyl]-4-[3-[4-(4-cyclohexyloxybutoxy)phenyl]propoxy]benzoic acid
CAS Number: 712313-35-4
Molecular Formula: C₃₄H₄₅NO₈
Molecular Weight: 595.723
Catalog: Signaling Pathways GPCR/G Protein Leukotriene Receptor
Create Date: 2016-12-17 21:20:01
Modify Date: 2024-01-09 14:06:25
HAMI 3379 is a potent and selective Cysteinyl leukotriene (CysLT2) receptor antagonist[1]. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation[2].

Name	3-[(3-carboxycyclohexyl)carbamoyl]-4-[3-[4-(4-cyclohexyloxybutoxy)phenyl]propoxy]benzoic acid
Synonyms	hami3379 3-[(3-Carboxycyclohexyl)carbamoyl]-4-(3-{4-[4-(cyclohexyloxy)butoxy]phenyl}propoxy)benzoic acid Benzoic acid, 3-[[(3-carboxycyclohexyl)amino]carbonyl]-4-[3-[4-[4-(cyclohexyloxy)butoxy]phenyl]propoxy]-

Description	HAMI 3379 is a potent and selective Cysteinyl leukotriene (CysLT2) receptor antagonist[1]. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury, and attenuates microglia-related inflammation[2].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> GPCR/G Protein >> Leukotriene Receptor Research Areas >> Inflammation/Immunology Research Areas >> Neurological Disease
Target	CysLT2
In Vitro	In a CysLT2 receptor reporter cell line, HAMI 3379 antagonizes leukotriene D4- (LTD4-) and leukotriene C4- (LTC4-) induced intracellular calcium mobilization with IC50 values of 3.8 nM and 4.4 nM, respectively. In contrast, HAMI 3379 exhibits very low potency on a recombinant CysLT1 receptor cell line (IC50>10000 nM)[1].
In Vivo	HAMI 3379 (ip; 0.025-0.4 mg/kg; 24 hours) attenuates the acute brain injury 24 hours after middle cerebral artery occlusion (MCAO) with effective doses of 0.1-0.4 mg/kg and a therapeutic window of ∼1 hour. It attenuates the neurological deficits, and reduces infarct volume, brain edema, and neuronal loss and degeneration 24 and 72 hours after MCAO[2]. HAMI 3379 (infused into the aortic cannula at a rate of 1% of the total flow rate; 0.01, 0.1, 1 μM; 20 min) concentration-dependently inhibits and reverses the LTC4-induced perfusion pressure increase and contractility decrease[1]. Animal Model: Male Sprague-Dawley rats (250-300 g) after MCAO[2] Dosage: 0.025, 0.05, 0.1, 0.2, 0.4 mg/kg Administration: IP; 24 hours Result: Attenuated the acute brain injury 24 hours after MCAO with effective doses of 0.1-0.4 mg/kg and a therapeutic window of ∼1 hour.
References	[1]. Wunder F, et al. Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor. Br J Pharmacol. 2010 May;160(2):399-409. [2]. Zhang XY, et al. HAMI 3379, a CysLT2 receptor antagonist, attenuates ischemia-like neuronal injury by inhibiting microglial activation. J Pharmacol Exp Ther. 2013 Aug;346(2):328-41.

Density	1.2±0.1 g/cm3
Boiling Point	797.7±60.0 °C at 760 mmHg
Molecular Formula	C₃₄H₄₅NO₈
Molecular Weight	595.723
Flash Point	436.3±32.9 °C
Exact Mass	595.314514
PSA	131.39000
LogP	6.48
Vapour Pressure	0.0±2.9 mmHg at 25°C
Index of Refraction	1.587

1245653-57-9	712313-35-4
1604290-12-1	1160166-16-4
1970720-69-4	1694188-65-2
1698620-51-7	1697481-99-4
1695865-50-9	1690604-79-5
1690553-20-8	1695733-75-5